{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T19:12:01Z","timestamp":1761765121778},"reference-count":58,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2002,10,1]],"date-time":"2002-10-01T00:00:00Z","timestamp":1033430400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2002,10]]},"DOI":"10.4065\/77.10.1085","type":"journal-article","created":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T20:19:36Z","timestamp":1232741976000},"page":"1085-1092","source":"Crossref","is-referenced-by-count":37,"title":["Statin Lipid-Lowering Therapy for Acute Myocardial Infarction and Unstable Angina: Efficacy and Mechanism of Benefit"],"prefix":"10.4065","volume":"77","author":[{"given":"R. Scott","family":"Wright","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph G.","family":"Murphy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kevin A.","family":"Bybee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen L.","family":"Kopecky","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marc","family":"LaBlanche","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.4065\/77.10.1085_bib1","series-title":"2000 Heart and Stroke Statistical Update","author":"American Heart Association","year":"1999"},{"key":"10.4065\/77.10.1085_bib2","series-title":"The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability From Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020","year":"1996"},{"key":"10.4065\/77.10.1085_bib3","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1056\/NEJM199511163332001","article-title":"Prevention of coronary artery disease with pravastatin in men with hypercholesterolemia","volume":"333","author":"Shepherd","year":"1995","journal-title":"N Engl J Med"},{"key":"10.4065\/77.10.1085_bib4","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1001\/jama.279.20.1615","article-title":"Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS\/TexCAPS","volume":"279","author":"Downs","year":"1998","journal-title":"JAMA"},{"key":"10.4065\/77.10.1085_bib5","first-page":"1383","article-title":"Randomised trial of cholesterol lowering in 4444 patients with coronary artery disease: the Scandinavian Simvastatin Survival Study (4S)","volume":"344","year":"1994","journal-title":"Lancet"},{"key":"10.4065\/77.10.1085_bib6","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJM199610033351401","article-title":"The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels","volume":"335","author":"Sacks","year":"1996","journal-title":"N Engl J Med"},{"key":"10.4065\/77.10.1085_bib7","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1056\/NEJM199811053391902","article-title":"Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels","volume":"339","author":"Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group","year":"1998","journal-title":"N Engl J Med"},{"key":"10.4065\/77.10.1085_bib8","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1001\/jama.285.19.2486","article-title":"Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III)","volume":"285","year":"2001","journal-title":"JAMA"},{"key":"10.4065\/77.10.1085_bib9","doi-asserted-by":"crossref","first-page":"3215","DOI":"10.1161\/01.CIR.99.25.3215","article-title":"Cholesterol lowering: should it continue to be the last thing we do?","volume":"99","author":"Waters","year":"1999","journal-title":"Circulation"},{"key":"10.4065\/77.10.1085_bib10","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1016\/S0140-6736(96)05190-2","article-title":"Statins do more than lower cholesterol","volume":"348","author":"Vaughan","year":"1996","journal-title":"Lancet"},{"key":"10.4065\/77.10.1085_bib11","doi-asserted-by":"crossref","first-page":"1643","DOI":"10.1001\/jama.279.20.1643","article-title":"Antiatherothrombotic properties of statins: implications for cardiovascular event reduction","volume":"279","author":"Rosenson","year":"1998","journal-title":"JAMA"},{"key":"10.4065\/77.10.1085_bib12","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1097\/00041433-199612000-00009","article-title":"Biological mechanisms for the clinical success of lipid-lowering in coronary artery disease and the use of surrogate end-points","volume":"7","author":"Kinlay","year":"1996","journal-title":"Curr Opin Lipidol"},{"key":"10.4065\/77.10.1085_bib13","doi-asserted-by":"crossref","first-page":"1712","DOI":"10.1161\/hq1101.098486","article-title":"Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors","volume":"21","author":"Takemoto","year":"2001","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.4065\/77.10.1085_bib14","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJM200111083451911","article-title":"Locking a leukocyte integrin with statins","volume":"345","author":"Frenette","year":"2001","journal-title":"N Engl J Med"},{"key":"10.4065\/77.10.1085_bib15","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S0009-8981(98)00179-X","article-title":"Cytokines and adhesion molecules in the course of acute myocardial infarction","volume":"280","author":"Pudil","year":"1999","journal-title":"Clin Chim ActA"},{"issue":"suppl 2","key":"10.4065\/77.10.1085_bib16","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1097\/00005344-199500252-00003","article-title":"Cytokines regulate vascular functions related to stability of the atherosclerotic plaque","volume":"25","author":"Libby","year":"1995","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.4065\/77.10.1085_bib17","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1136\/heart.83.3.361","article-title":"The pathophysiology of acute coronary syndromes","volume":"83","author":"Davies","year":"2000","journal-title":"Heart"},{"key":"10.4065\/77.10.1085_bib18","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1016\/S0011-393X(05)80318-2","article-title":"Changes induced by pravastatin treatment on hemostatic and fibrinolytic patterns in patients with type IIB hyperlipoproteinemia","volume":"55","author":"Avellone","year":"1994","journal-title":"Curr Ther Res Clin Exp"},{"key":"10.4065\/77.10.1085_bib19","first-page":"829","article-title":"Hypercoagulable state in patients with hypercholesterolemia: effects of pravastatin","volume":"14","author":"Wada","year":"1992","journal-title":"Clin Ther"},{"key":"10.4065\/77.10.1085_bib20","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1177\/009127009203200609","article-title":"Lovastatin alters blood rheology in primary hyperlipoproteinemia: dependence on lipoprotein(a)?","volume":"32","author":"Koenig","year":"1992","journal-title":"J Clin Pharmacol"},{"key":"10.4065\/77.10.1085_bib21","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/0002-9149(93)90858-A","article-title":"Effects of pravastatin in patients with serum total cholesterol levels from 5.2 to 7.8 mmol\/liter (200 to 300 mg\/dL) plus two additional atherosclerotic risk factors","volume":"72","author":"Pravastatin Multinational Study Group for Cardiac Risk Patients","year":"1993","journal-title":"Am J Cardiol"},{"key":"10.4065\/77.10.1085_bib22","doi-asserted-by":"crossref","first-page":"512","DOI":"10.1002\/j.1552-4604.1991.tb03729.x","article-title":"Lovastatin therapy in hypercholesterolemia: effect on fibrinogen, hemorrheologic parameters, platelet activity, and red blood cell morphology","volume":"31","author":"Beigel","year":"1991","journal-title":"J Clin Pharmacol"},{"key":"10.4065\/77.10.1085_bib23","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1007\/BF01696223","article-title":"Effects of long-term treatment with lovastatin on the clotting system and blood platelets","volume":"64","author":"Mayer","year":"1992","journal-title":"Ann Hematol"},{"key":"10.4065\/77.10.1085_bib24","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/0021-9150(89)90036-1","article-title":"Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in type IIa hypercholesterolemic patients","volume":"79","author":"Davi","year":"1989","journal-title":"Atherosclerosis"},{"key":"10.4065\/77.10.1085_bib25","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1161\/01.ATV.15.2.247","article-title":"Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia","volume":"15","author":"Notarbartolo","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.4065\/77.10.1085_bib26","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1161\/01.ATV.15.6.759","article-title":"Platelet cytosolic CA2+ and membrane dynamics in patients with primary hypercholesterolemia: effects of pravastatin","volume":"15","author":"Le Quan Sang","year":"1995","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"10.4065\/77.10.1085_bib27","doi-asserted-by":"crossref","first-page":"3172","DOI":"10.1161\/01.CIR.92.11.3172","article-title":"Hyperlipidemia and coronary disease: correction of the increased thrombogenic potential with cholesterol reduction","volume":"92","author":"Lacoste","year":"1995","journal-title":"Circulation"},{"issue":"suppl A","key":"10.4065\/77.10.1085_bib28","doi-asserted-by":"crossref","first-page":"413A","DOI":"10.1016\/S0735-1097(96)82590-3","article-title":"Comparative effect of pravastatin and simvastatin on platelet-thrombus formation in hypercholesterolemic coronary patients [abstract]","volume":"27","author":"Lacoste","year":"1996","journal-title":"J Am Coll Cardiol"},{"key":"10.4065\/77.10.1085_bib29","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1056\/NEJM199502233320801","article-title":"Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease","volume":"332","author":"Treasure","year":"1995","journal-title":"N Engl J Med"},{"key":"10.4065\/77.10.1085_bib30","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1097\/00041433-199910000-00008","article-title":"Inflammation markers and coronary heart disease","volume":"10","author":"Tracy","year":"1999","journal-title":"Curr Opin Lipidol"},{"key":"10.4065\/77.10.1085_bib31","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1161\/01.CIR.98.9.839","article-title":"Inflammation, pravastatin, and the risk of coronary events after myocardial infarction in patients with average cholesterol levels","volume":"98","author":"Ridker","year":"1998","journal-title":"Circulation"},{"key":"10.4065\/77.10.1085_bib32","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1161\/01.CIR.100.3.230","article-title":"Long-term effects of pravastatin on plasma concentration of C-reactive protein","volume":"100","author":"Ridker","year":"1999","journal-title":"Circulation"},{"key":"10.4065\/77.10.1085_bib33","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1056\/NEJM200106283442601","article-title":"Measurement of C-reactive protein for the targeting of statin therapy in the primary prevention of acute coronary events","volume":"344","author":"Ridker","year":"2001","journal-title":"N Engl J Med"},{"key":"10.4065\/77.10.1085_bib34","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.286.1.64","article-title":"Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation\/CRP evaluation (PRINCE): a randomized trial and cohort study","volume":"286","author":"Albert","year":"2001","journal-title":"JAMA"},{"key":"10.4065\/77.10.1085_bib35","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1038\/89058","article-title":"Statins selectively inhibit leukocyte function antigen-1 by binding to a novel regulatory integrin site","volume":"7","author":"Weitz-Schmidt","year":"2001","journal-title":"Nat Med"},{"key":"10.4065\/77.10.1085_bib36","doi-asserted-by":"crossref","first-page":"3227","DOI":"10.1161\/01.CIR.99.25.3227","article-title":"Cholesterol reduction rapidly improves endothelial function after acute coronary syndromes: the RECIFE (reduction of cholesterol in ischemia and function of the endothelium) trial","volume":"99","author":"Dupuis","year":"1999","journal-title":"Circulation"},{"key":"10.4065\/77.10.1085_bib37","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1161\/01.CIR.95.5.1126","article-title":"Simvastatin, an HMG-coenzyme A reductase inhibitor, improves endothelial function within 1 month","volume":"95","author":"O'Driscoll","year":"1997","journal-title":"Circulation"},{"key":"10.4065\/77.10.1085_bib38","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1161\/01.CIR.97.12.1129","article-title":"Upregulation of endothelial nitric oxide synthase by HMG-CoA reductase inhibitors","volume":"97","author":"Laufs","year":"1998","journal-title":"Circulation"},{"key":"10.4065\/77.10.1085_bib39","doi-asserted-by":"crossref","first-page":"771","DOI":"10.1016\/S0002-9149(00)01501-0","article-title":"Effect of concomitant or very early statin administration on in-hospital mortality and reinfarction in patients with acute myocardial infarction","volume":"87","author":"Bybee","year":"2001","journal-title":"Am J Cardiol"},{"issue":"suppl 2","key":"10.4065\/77.10.1085_bib40","first-page":"II","article-title":"Early statin use in acute myocardial infarction is associated with a reduced hospital mortality: results of the Mitra-2 [abstract]","volume":"102","author":"Schiele","year":"2000","journal-title":"Circulation"},{"issue":"suppl 2","key":"10.4065\/77.10.1085_bib41","first-page":"II","article-title":"Role of statins in patients with acute coronary syndromes [abstract]","volume":"102","author":"Hamm","year":"2000","journal-title":"Circulation"},{"issue":"suppl 2","key":"10.4065\/77.10.1085_bib42","first-page":"II","article-title":"Initiation of statin therapy immediately after stent implantation: profound benefit in patients with acute coronary syndromes [abstract]","volume":"102","author":"Walter","year":"2000","journal-title":"Circulation"},{"key":"10.4065\/77.10.1085_bib43","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1001\/jama.285.4.430","article-title":"Early statin treatment following acute myocardial infarction and 1-year survival","volume":"285","author":"Stenestrand","year":"2001","journal-title":"JAMA"},{"issue":"suppl 2","key":"10.4065\/77.10.1085_bib44","first-page":"II","article-title":"Differential benefit from treatment with a statin agent at hospital discharge in non-ST elevation MI compared to ST elevation MI [abstract]","volume":"102","author":"Bybee","year":"2000","journal-title":"Circulation"},{"key":"10.4065\/77.10.1085_bib45","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/S0140-6736(00)04257-4","article-title":"Effect of lipid-lowering therapy on early mortality after acute coronary syndromes: an observational study","volume":"357","author":"Aronow","year":"2001","journal-title":"Lancet"},{"issue":"suppl A","key":"10.4065\/77.10.1085_bib46","first-page":"316A","article-title":"Lipid lowering drug therapy initiated during hospitalization for acute MI is associated with lower postdischarge 1-year mortality [abstract]","volume":"37","author":"Giugliano","year":"2001","journal-title":"J Am Coll Cardiol"},{"issue":"suppl A","key":"10.4065\/77.10.1085_bib47","first-page":"334A","article-title":"Early statin therapy is associated with markedly lower mortality in patients with acute coronary syndromes: observations from OPUS-TIMI 16 [abstract]","volume":"37","author":"Cannon","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"10.4065\/77.10.1085_bib48","doi-asserted-by":"crossref","first-page":"3087","DOI":"10.1001\/jama.287.23.3087","article-title":"Early statin initiation and outcomes in patients with acute coronary syndromes","volume":"287","author":"Newby","year":"2002","journal-title":"JAMA"},{"issue":"suppl 1","key":"10.4065\/77.10.1085_bib49","first-page":"I","article-title":"The short term results of combined use of pravastatin with thrombolytic therapy in acute myocardial infarction [abstract]","volume":"100","author":"Kayikcioglu","year":"1999","journal-title":"Circulation"},{"key":"10.4065\/77.10.1085_bib50","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jama.285.13.1711","article-title":"Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial","volume":"285","author":"Schwartz","year":"2001","journal-title":"JAMA"},{"key":"10.4065\/77.10.1085_bib51","unstructured":"van Boven AJ, Liem A. Fluvastatin on Risk Diminishing After Acute Myocardial Infarction (FLORIDA). Presented at: American Heart Association Scientific Session 2000; November 12-15, 2000; New Orleans, LA. Available at: www.acc.org\/education\/online\/trials\/aha00\/florida.htm. Accessibility verified August 21, 2002."},{"key":"10.4065\/77.10.1085_bib52","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1007\/s003920050329","article-title":"Short- and long-term effects of intensified versus conventional antilipidemic therapy in patients with coronary heart disease: results from the Lipid-Coronary Artery Disease (L-CAD) Study [in German]","volume":"88","author":"Arntz","year":"1999","journal-title":"Z Kardiol"},{"key":"10.4065\/77.10.1085_bib53","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0002-9149(00)01230-3","article-title":"Beneficial effects of pravastatin (+\/-colestyramine\/niacin) initiated immediately after a coronary event (the randomized Lipid-Coronary Artery Disease [L-CAD] Study)","volume":"86","author":"Arntz","year":"2000","journal-title":"Am J Cardiol"},{"key":"10.4065\/77.10.1085_bib54","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1097\/00045415-200203000-00007","article-title":"The case for early statin therapy in acute coronary syndromes","volume":"10","author":"Arntz","year":"2002","journal-title":"Cardiol Rev"},{"key":"10.4065\/77.10.1085_bib55","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1067\/mhj.2001.116959","article-title":"The A-to-Z Trial: methods and rationale for a single trial investigating combined with use of low-molecular-weight heparin with the glycoprotein IIb\/IIIa inhibitor tirofiban and defining the efficacy of early aggressive simvastatin therapy","volume":"142","author":"Blazing","year":"2001","journal-title":"Am Heart J"},{"key":"10.4065\/77.10.1085_bib56","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/S0002-9149(02)02201-4","article-title":"Design of the Pravastatin or Atorvastatin Evaluation and Infection Therapy (PROVE IT)-TIMI 22 trial","volume":"89","author":"Cannon","year":"2002","journal-title":"Am J Cardiol"},{"key":"10.4065\/77.10.1085_bib57","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1161\/01.CIR.103.1.38","article-title":"Use of lipid-lowering medications at discharge in patients with acute myocardial infarction: data from the National Registry of Myocardial Infarction 3","volume":"103","author":"Fonarow","year":"2001","journal-title":"Circulation"},{"key":"10.4065\/77.10.1085_bib58","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/S0140-6736(02)09327-3","article-title":"MRC\/BHF Heart Protection Study of cholesterol lowering with simvastatin 20,536 high-risk individuals: a randomised placebo-controlled trial","volume":"360","year":"2002","journal-title":"Lancet"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611625299?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611625299?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,12,22]],"date-time":"2018-12-22T03:24:36Z","timestamp":1545449076000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611625299"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2002,10]]},"references-count":58,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2002,10]]}},"alternative-id":["S0025619611625299"],"URL":"https:\/\/doi.org\/10.4065\/77.10.1085","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2002,10]]}}}